BARCELONA (Reuters) – An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.
The result is not conclusive, because the analysis was done…
Early data suggest Sanofi, Regeneron drug may halve heart risk
No comments:
Post a Comment